Taxus Cardium Pharmaceuticals Group Inc (CRXM)

[Altitrade Partners]

6.1 SEC Filings. The Company has engaged Marcum, LLP (“Marcum”) to prepare the Company’s financial statements for the years ended December 31, 2017, 2018 and 2019 that are required to be filed with Securities and Exchange Commission (“SEC”) pursuant to the Exchange Act in order to cause the Company to become current with its reporting obligations. The expense incurred for such financial statement preparation, up to $120,000, will be paid by the Company from the proceeds of the sale of the Shares. It is understood that the Company is delinquent in its SEC reporting obligations and the Company and its officers and directors shall use their reasonable best efforts to assist Marcum so as to ensure that the Company becomes current with such obligations. Within four (4) Business Days after the Closing, the Company will file a current report on Form 8-K disclosing the change of control contemplated by this Agreement.

https://contracts.justia.com/companies/gene-biotherapeutics-inc-7110/contract/119376/